Explore the Agenda
Introduction to ADCs Day
Are you new to the ADC field? If so, join our ADC 101 day to get your ADC knowledge up to scratch ahead of the scientific programme days.
Targeted towards those new to ADCs, this seminar day will provide you with the critical knowledge gained over years of research and failed clinical trials that culminated in the presently approved ADCs and booming innovation in the field.
Led by a long-standing expert and KOL in the field, join this one-stop-shop of ADC learning to establish a
core understanding of the essential elements in ADC discovery and early development.
Check In, Morning Coffee & Light Refreshments
The morning session will cover:
- Understanding the foundational lessons that shaped modern ADC design and helped overcome early development challenges
- Evaluating key ADC components, including payload selection and linker chemistry, to optimise efficacy and safety
- Assessing the impact of conjugation site selection on ADC performance, stability, and therapeutic outcomes
Lunch Break & Networking
The afternoon session will cover:
- Understanding the biological principles of ADCs and selecting the most appropriate target and antibody format
- Analysing the key choices, trade-offs, and design considerations across the ADC chemistry toolbox
- Evaluating preclinical in vivo efficacy data and the critical factors that inform successful ADC development and translation to the clinic
End of Introduction to ADCs Day
ADC Licensing, Partnering & Investment Session
Financing the Next Generation of Safer, More Effective ADCs Through Biopharma Partnerships, Collaborations & Investment Strategies
Join leading business development executives, biotech innovators, and investors for an exclusive discussion on the booming ADC dealmaking landscape. In 2026 alone, the ADC sector has continued to attract major investment, highlighted by Gilead’s acquisition of Tubulis GmbH for up to $5 billion and Novartis’ acquisition of Myricx Bio to access its next-generation ADC payload platform and pipeline. Major licensing activity has also continued, including multi-billion-dollar ADC partnerships focused on novel targets, payloads, and conjugation technologies.
Discover what drives licensing decisions, investment strategies, and M&A activity, learn what makes ADC assets stand out to partners, and gain insight into where the market is headed next. As large pharma companies increasingly compete for differentiated ADC platforms and clinical-stage assets, understanding the data, innovation, and risk factors behind successful deals has never been more important.
Speakers Include: